Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (21405)	4/26/1999 5:13:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

For the record here are the two patents Vivus:http://164.195.100.11/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/srchnum.htm&r=1&f=G&l=50&s1='5877216'.WKU.&OS=PN/5877216&RS=PN/5877216 Wysor:http://164.195.100.11/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=/netahtml/search-adv.htm&r=1&f=G&l=50&d=PALL&S1=5891915.WKU.&OS=PN/5891915&RS=PN/5891915 Seems to me that the Vivus patent makes redundant the Wysor patent which is also clearly more superficial. Neither of the patent applications give data on humans or cats or rabbits, perhaps these in accompanying documents?? Regarding the Wysor human data, are we not here in the same situation as with Erogenex, if you have some humans who say it's great this carries some kind of weight? But not the weight of phase I trials (for safety) nor phase II (safety + efficacy). Since the Vivus patent is for human use I do not see what difference the human data the Wysors's have, such as it is, can make. Maybe Mark Stang could comment.